HER2+ early breast cancers where shorter-course trastuzumab could be an option
byEuropean Society for Medical OncologyCredit: European Society for Medical OncologyWomen with HER2-positive early breast cancer with small tumours have similar disease-free survival and lower r
Updated on: December 18,2023
17
HER2+ early breast cancers where shorter-course trastuzumab could be an option
byEuropean Society for Medical OncologyCredit: European Society for Medical OncologyWomen with HER2-positive early breast cancer with small tumours have similar disease-free survival and lower r
Updated on:December 18,2023
17
